logo-loader
Zynerba Pharmaceuticals

Zynerba rockets as investors await CEO's presentation at London conference

The 2019 HC Wainwright Global Life Sciences Conference will take place on April 9 at the Grosvenor House

double-decker bus
Zynerba Pharmaceuticals focuses on treating cannabinoid therapies for rare neuropsychiatric disorders

Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) soared Wednesday on the back of news that its CEO Armando Anido will present a company overview at the 2019 HC Wainwright Global Life Sciences Conference in the UK this month.

The presentation will take place on April 9 at 12:10 pm at the Grosvenor House in London.

Devon, Pennsylvania-based Zynerba is on track to report top-line results in the second half of the year from Phase 2/3 trials of its Zygel (ZYN002), a CBD gel treatment for children and adolescents with Fragile X syndrome, the most common form of inherited learning disability and attention deficit disorder.

READ: Zynerba’s 4Q shows momentum as it heads into key clinical trial

Enthused by the publicity the London conference will bring, investors sent Zynerba shares up 19.9% to $7.77 in afternoon trade.

Zynerba Pharmaceuticals focuses on treating cannabinoid therapies for rare neuropsychiatric disorders.

The company’s cash and cash equivalent position as of December 31, 2018 was $59.8 million while its research and development expenses for the fourth quarter came in at $4.9 million. 

Management said last month it believes its cash position is “sufficient to fund operations” beyond the potential approval in Fragile X syndrome and “into the first quarter of 2021.”

Contact Ellen Kelleher at [email protected]

Quick facts: Zynerba Pharmaceuticals

Price: $8.45

Market: NASDAQ
Market Cap: $193.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read